MADIT II - The Multicenter Automatic Defibrillator Implantation Trial


Status: Completed in 2001

The first trial to show the lifesaving benefits of Implantable Cardiac Defibrillators (ICD) without requiring patients to have a documented history of abnormal heart rhythms.


 

Results

Mortality over an average follow-up of 20 months

Conventional Group
(n=490
)
ICD Group
(n=742)
Hazard Ratio
(95% CI)
P-value
19.8 (97) 14.2 (105) .69 (0.51-0.93) 0.016

 

  • There was a 31% reduction in the risk of death at any interval among patients in the defibrillator group as compared with patients in the conventional-therapy group. 
  • The cumulative survival curves represent a relative decrease in death rates in the defibrillator group (95% confidence limits) of 12% at 1 year (-27 to 40%), 28% at 2 years (4 to 46%), and 29% at 3 years (5 to 46%).


MADIT - II Results Graph


Design

MADIT II Design Graph

Patients were randomized into two treatment arms in a 3:2 ratio.

Patients in the first arm were treated with conventional drug treatment and also implanted with an ICD.

The second group was treated exclusively with conventional drug treatment, as prescribed by the patient's attending physician (control arm).

Patients were seen in the follow-up clinic at 1 month after randomization, and then at 3-month intervals until the termination date of the study or death.


Patient Population

Eligible study participants included both male and female patients over 21 years of age that had experienced an MI at least 30 days prior to study enrollment and demonstrated an ejection fraction (EF) ≤ 30%.

Some of the exclusion criteria were

  • Prior cardiac arrest
  • Syncope unrelated to an acute MI
  • NYHA Class IV
  • CABG or non-CABG revascularization less than 3 months prior to enrollment
  • Use of antiarrhythmic agents, except for atrial arrhythmias
  • Comorbidity associated with decreased survival for trial duration.

76 Centers worldwide

  • 71 U.S.
  • 5 European

1232 patients enrolled


Clinical Relevance

To evaluate the effect of prophylactic ICD therapy on survival in patients with prior MI and LV dysfunction.

The primary endpoint was death from any cause

First trial to show the lifesaving benefits of ICDs without requiring patients to have a documented history of abnormal heart rhythms


References

1 - Moss A, Cannom D, Daubert J et al. Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): Design and Clinical Protocol. Ann Noninvasive Electrocardiol 1999;4:83-91.

2 - Moss A, Zareba W, Hall W, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.

Bookmark and Share

Downloadable Resource

Download slide deck for the MADIT II Trial

This is the image description.  MADIT II Trial Slides (PPT)

 

Important Risk Information

 

Access trial information

 

CRM6-5390-0910